Fed. Circ. Sides With GSK, Others In Argatroban IP Row
A three-judge panel denied defendant-appellant Barr's challenge to a lower court's judgment that the Mitsubishi patent-in-suit was valid.
Mitsubishi and the other plaintiffs slapped Barr with the suit after the company sought approval for a generic version of injectable Argatroban, and Barr argued that the four patent...
To view the full article, register now.